Abstract:e20036 Background: Mucosal melanoma (MM) is the second common subtype in Asians with a percentage of 22-25%; but there have been few epidemiologic studies. So we performed a retrospective analysis of MM about its clinical presentation, gene mutation, systemic therapy (tx) and prognosis. Methods: Using institutional databases, we identified patients (pts) with MM who were treated in Chinese melanoma centers between 2006-2014 with basic demographics and clinical outcomes. Results: 463 MM pts were included. Median age at diagnosis 56 years (range, 17-86); 61% female; primary site: 149 anal-rectal, 125 genitourinary, 174 head/neck, 15 others. Mutation (mut) status: 14.1% (45/319) KIT mut; 9.7% (31/319) BRAF mut; 10.3% (33/319) NRAS mut. Stage I-II/ III/IV at referring – 36%/17%/47%, M1a/b/c – 17%/18%/65%. The median overall survival (mOS) was 28.0 mo (95% CI 25.1-30.9 mo). Multivariate analysis showed that clinical stage and LDH level were significant prognostic factors for OS. The application of adjuvant therapy and LDH level were significant prognostic factors for disease free survival. For 293 pts who developed stage IV, mOS was 14.0 mo, for M1a, M1b, M1c, 20.2, 16.0, 11.1 mo respectively (p = .004). In 1st-line setting, the objective response rate (RR), disease control rate (DCR) and median progress free time (PFS) was 11.8%, 54.8%, and 3.1 mo (95% CI 2.6-3.8 mo), most of the pts using dacarbazine/temozolomide, cisplatin plus rhEndostatin had RR, DCR and PFS, 12.3%, 64.6%, and 4.5 mo respectively. In 2nd-line setting, paclitaxel plus carboplatin was common regimen, RR, DCR and PFS was 8.3% 61.1% and 3.3 mo (95% CI 2.0-4.4 mo). The mPFS of 3rd-line tx (including Abraxane, investigational targeted drugs, etc) was 1.3 mo without complete regression and partial regression. 8/20 pts harboring c-kit mutation used imatinib, 3/8 pts had SD for a median PFS of 6.7 mo. 5/15 pts harboring BRAF mutation used vemurafenib, 3/5 pts got response, mPFS cannot be evaluated. Conclusions: The prognosis for MM is still poor, clinical stage has its significance for OS. For pts with stage IV, the efficacy of systemic tx includes chemotherapy and targeted therapy is modest. Further investigation into the biology and treatment of MM is needed.

Clinical significance of ERBB4 gene mutations and ERBB4 protein expression in Chinese patients with mucosal and acral melanomas

Mutations of PTEN Gene in 117 Chinese Patients with Malignant Melanoma and Their Clinical Significance

Clinicopathological and Prognostic Significance of MUC4 Expression in Cancers: Evidence from Meta-Analysis.

The Absence of the ERBB4 Hotspot Mutations in Melanomas in Patients from Southern China

Comprehensive Genomic Profiling Reveals Distinct Patterns of Driver Mutations and Chromosomal Alterations in Acral and Mucosal Melanomas.

Distinct Genomic Traits Of Acral And Mucosal Melanomas Revealed By Targeted Mutational Profiling

BRAF, C-KIT, and NRAS mutations correlated with different clinicopathological features: an analysis of 691 melanoma patients from a single center

KRAS, BRAF and PIK3CA Mutations and the Loss of PTEN Expression in Chinese Patients with Colorectal Cancer.

MUC4 Isoforms Expression Profiling and Prognosis Value in Chinese Melanoma Patients.

BRAF mutation in Chinese melanoma patients

Aberrations of KIT, BRAF, NRAS, and PDGFRA in Chinese Melanoma Patients and Their Significance: Large, Scale Analysis of 644 Patients.

Gene mutations and clinical prognosis of mucosal melanoma in different locations of head and neck

Analysis of PBRM 1 gene mutations in 53 Chinese patients with clear cell renal cell carcinoma

MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases

Mutational Profiling of Melanomas in Patients from the Southeast Coast of China.

Analysis of KIT Expression and Gene Mutation in Human Acral Melanoma: with a Comparison Between Primary Tumors and Corresponding Metastases/recurrences.

Clinical Presentation, Systemic Therapy and Prognosis of Mucosal Melanoma, A Study of 463 Consecutive Cases

Analysis of extracellular regulated protein kinase activation and clinical characteristics in patients with nasal mucosa melanomas

Gene Mutation Characteristics and Clinical Prognosis of Head and Neck Mucosal Melanoma

Clinical presentation, histology and prognosis of mucosal melanoma in ethnic Chinese: A study of 212 consecutive cases

Genetic Alteration of Chinese Patients with Rectal Mucosal Melanoma.